select trial semaglutide nejm heart failure and cardiovascular outcomes in patients with obesity and prevalent failure: a prespecified analysis of the Semaglutide and Cardiovascular Outcomes in – Long-term kidney outcomes of semaglutide

A full dataset presented at the annual Scientific Sessions meeting of the American Heart Association on Saturday suggests that the GLP-1 obesity drug Wegovy (semaglutide) decreased relative risk by 20% of a composite primary endpoint measure which included death from cardiovascular causes, non-fatal myocardial infarction and non-fatal stroke

Metformin promotes weight loss by regulating the bodys response to insulin, reducing blood sugar levels, decreasing appetite cravings, and lowering the tendency to store fat, especially belly fat

### Tuesday **Pros:** Nausea window on Wednesday/Thursday, slightly lighter for many

Always follow label directions and professional advice

Blueberry Flavor and Easy Daily Use

So that means today people are eating up to 25 times more omega-6 than they have been historically